$8.740
-0.419 (-4.79%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
BBOT 相似圖表分析預測
Alphio's BBOT stock price prediction model matches the current BridgeBio Oncology Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $8.68 (-0.74%). The 1-week path is $8.83 (+1.08%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
該買進 BridgeBio Oncology Therapeutics Inc 股票嗎？
Helix Acquisition Corp II (BBOT) is not a good buy right now due to its current price of $8.74, which is significantly below analyst price targets ranging from $22 to $29. The stock has a low RSI of 33.785, indicating it is oversold, but the negative catalysts such as a consistent decline in net income and a projected EPS of -0.71 suggest ongoing financial struggles. The main risk is the high forward P/E ratio of 0, indicating uncertainty in future earnings.
BBOT 股價於 Friday 收在 $8.74，此前下跌 -4.79%
BridgeBio Oncology Therapeutics Inc (BBOT) last closed at $8.74, losing -4.79%. These facts feed the 1-day and 1-week BBOT price prediction above.
預測驅動因素
BridgeBio Oncology Therapeutics Inc（BBOT）的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
相似圖表形態
近期走勢與 BBOT 最接近的股票，依相似度排序。
BBOT 季節性分析
Historically the probability of a positive August return for BBOT is 11.43%. October offers the highest probability of a positive month at 100.00%, while February is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。